Discovery of novel CSF biomarkers to predict progression in dementia using machine learning

  • Dea Gogishvili
  • , Eleonora M Vromen
  • , Sascha Koppes-den Hertog
  • , Afina W Lemstra
  • , Yolande A L Pijnenburg
  • , Pieter Jelle Visser
  • , Betty M Tijms
  • , Marta Del Campo
  • , Sanne Abeln
  • , Charlotte E Teunissen
  • , Lisa Vermunt

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline within dementia patients. First, longitudinal mini-mental state examination scores (MMSE) of 210 dementia patients were used to create fast and slow progression groups. Second, we trained random forest classifiers on CSF proteomic profiles and obtained a well-performing prediction model for the progression group (ROC-AUC = 0.82). As a third step, Shapley values and Gini feature importance measures were used to interpret the model performance and identify top biomarker candidates for predicting the rate of cognitive decline. Finally, we explored the potential for each of the 20 top candidates in internal sensitivity analyses. TNFRSF4 and TGF [Formula: see text]-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. Proteins of which a low concentration was associated with fast progression were enriched for cell signalling and immune response pathways. None of our top markers stood out as strong individual predictors of subsequent cognitive decline. This could be explained by small effect sizes per protein and biological heterogeneity among dementia patients. Taken together, this study presents a novel progression biomarker identification framework and protein leads for personalised prediction of cognitive decline in dementia.

Original languageEnglish
Article number6531
Pages (from-to)1-13
Number of pages13
JournalScientific Reports
Volume13
Issue number1
DOIs
Publication statusPublished - Dec 2023

Bibliographical note

© 2023. The Author(s).

Funding

Research of DG, CT, and SA are supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE). CT is supported by JPND (bPRIDE)), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. MC acknowledges support from the Selfridges Group Foundation, Alzheimer Netherland, JPND (bPRIDE), the attraction talent fellowship of Comunidad de Madrid, and I+D+i 2020 projects from the Spanish ministry of science and innovation. MC acknowledges support from the Selfridges Group Foundation, Alzheimer Netherland, JPND (bPRIDE), the attraction talent fellowship of Comunidad de Madrid, and I+D+i 2020 projects from the Spanish ministry of science and innovation. LV acknowledges the funding from Stichting Dioraphte. CT is the recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and HealthHolland, Topsector Life Sciences and Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. CT has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Olink, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology and Neuroinflammation, and is editor of a Neuromethods book Springer. LV has received grants or consultancy fees from Olink, Roche, ZonMw, Dioraphte and Alzheimer Nederland, paid to her institution. The rest of the authors do not have any competing interest to declare.

FundersFunder number
AC-Immune
Edwin Bouw Fonds and Gieskes-Strijbisfonds
HealthHolland
I+D+i 2020
Topsector Life Sciences and Health20106
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Eli Lilly and Company
Comunidad de Madrid
EU Joint Programme – Neurodegenerative Disease Research
Health~Holland
European Commission860197
ZonMw
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Ministerio de Ciencia e Innovación
Stichting Dioraphte
Alzheimer Nederland
Selfridges Group Foundation

    Keywords

    • Humans
    • Alzheimer Disease/diagnosis
    • Amyloid beta-Peptides/cerebrospinal fluid
    • tau Proteins/cerebrospinal fluid
    • Proteomics
    • Biomarkers/cerebrospinal fluid
    • Cognitive Dysfunction/diagnosis
    • Machine Learning
    • Disease Progression

    Fingerprint

    Dive into the research topics of 'Discovery of novel CSF biomarkers to predict progression in dementia using machine learning'. Together they form a unique fingerprint.

    Cite this